Multi-micronutrient Supplementation During Peri-conception and Congenital Heart Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02537392|
Recruitment Status : Recruiting
First Posted : September 1, 2015
Last Update Posted : January 13, 2017
|Condition or disease||Intervention/treatment||Phase|
|Congenital Heart Disease||Dietary Supplement: Vitamin B Complex and Folic Acid Dietary Supplement: Iron and Folic Acid Dietary Supplement: Folic Acid||Not Applicable|
Congenital heart disease (CHD) is among the most prevalent congenital abnormalities with an incidence of about 8-12/1,000 live births, and is also the leading cause of infant morbidity and death from birth defects. A series of studies pointed out that the poor nutritional status of the mother during peri-conception might be the important cause of CHD. In maternal folic acid/ vitamin B deficiency homocysteine accumulates in the serum, and elevated circulating homocysteine concentrations have been associated with the risk of CHD. However, it is still questionable whether multiple vitamin B supplements during peri-conception can reduce CHD risk more effectively compared with the supplement of folic acid alone. Moreover, one randomized controlled trial performed in Shaanxi China confirmed that the supplement of iron and folic acid during pregnancy can significantly reduce early neonatal deaths. It is noteworthy that one-fourth of newborn deaths are attributable to birth defects. Thus, it is worthwhile to investigate whether iron supplement can reduce the risk of CHD.
This community-based randomized controlled trial will assess and compare the impact of daily oral supplements of vitamin B complex along with folic acid or supplements of iron plus folic acid vs. folic acid alone given to women during peri-conception on CHD. It will also assess the effects of the three different supplementations on other pregnancy outcomes and maternal health. The study will be conducted in three rural poor counties including Xunyi, Changwu, and Bin, which are located in Shaanxi Province of Northwest China. All participants will sign informed consent before the study. The investigators hypothesize that the newborn infants of women receiving supplements of vitamin B complex along with folic acid or supplements of iron plus folic acid will experience a reduction in the prevalence of infants with the pulse oxygen saturation less than 95% and other adverse pregnancy outcomes compared with those receiving folic acid alone. The results of this trial will provide evidence needed to formulate policy on maternal micronutrient supplementation during peri-conception and the rationale for the necessary investment of public funds to implement appropriate programs against birth defects.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||9374 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Primary Prevention of Multi-micronutrient Supplementation During Peri-conception Against Congenital Heart Disease: A Community-based Randomised Controlled Trial in China|
|Study Start Date :||September 2015|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||June 2019|
Experimental: Vitamin B Complex and Folic Acid
Daily supplements containing vitamin B1 (2 mg), vitamin B2 (2 mg), vitamin B6 (2 mg), vitamin B12 (2 μg), calcium pantothenate (2 mg), nicotinamide (15 mg) and folic acid (0.4 mg).
Dietary Supplement: Vitamin B Complex and Folic Acid
Daily oral dose containing 2 mg vitamin B1, 2 mg vitamin B2, 2 mg vitamin B6, 2 μg vitamin B12, 2 mg calcium pantothenate, 15 mg nicotinamide and 0.4 mg folic acid.
Experimental: Iron and Folic Acid
Daily supplements of iron (60 mg) and folic acid (0.4 mg).
Dietary Supplement: Iron and Folic Acid
Daily oral dose of 60 mg iron and 0.4 mg folic acid.
Active Comparator: Folic Acid
Daily supplement of 0.4 mg folic acid.
Dietary Supplement: Folic Acid
Daily oral dose of 0.4 mg folic acid.
- Neonatal pulse oximetry oxygen saturation measured by pulse oximetry [ Time Frame: 6-72 hours after delivery ]Neonatal pulse oximetry oxygen saturation (SpO2) is tested by pulse oximetry in babies aged between 6 h and 72 h after birth. Pulse oximetry testing is repeated 4 h later if the first measurement is between 90% and 95%. The result of SpO2 will be reported as a dichotomous variable, in which the result is deemed positive if an SpO2 less than 95% is obtained both on the right hand and on either foot on two measures, separated by 4 h; a difference between the two extremities was more than 3% on two measures, separated by 4 h; or any measure is less than 90%. The result of SpO2 will also be reported as a continuous variable.
- Incidence of congenital heart disease and the subtypes [ Time Frame: Half a year after delivery ]Congenital heart disease will be diagnosed by trained clinicians with the help of echocardiography, pulse oximetry, clinical examination, cardiac surgery, or autopsy. The incidence of congenital heart disease and the subtypes will be reported in each group.
- Incidence of birth defects and the subtypes [ Time Frame: Half a year after delivery ]Birth defects will be diagnosed by trained clinicians. The incidence of birth defects and the subtypes will be reported in each group.
- Birth weight measured by baby scale [ Time Frame: Within 1 hours of delivery ]Birth weight will be measured within 1 hour of delivery using a baby scale with the precision to the nearest 50 gram.
- Incidence of low birth weight [ Time Frame: Within 1 hour of delivery ]Birth weight will be measured within 1 hour of delivery using a baby scale. The incidence of low birth weight will be reported in each group based on the criteria of birth weight less than 2500 gram.
- Gestational age at birth [ Time Frame: At delivery ]Gestational age at birth will be measured as completed days based on the last menstrual period.
- Incidence of preterm birth [ Time Frame: At delivery ]Gestational age at birth will be measured as completed days based on the last menstrual period. The incidence of preterm birth (infant born less than 37 weeks gestational age) will be reported in each group.
- Incidence of perinatal mortality [ Time Frame: Between 28 weeks of gestational duration and 7 days after delivery ]The incidence of perinatal mortality (Infants death between 28 weeks of gestational duration and 7 days after delivery) will be reported in each group.
- Incidence of stillbirth [ Time Frame: At delivery ]The incidence of stillbirth (infants death at delivery) will be reported in each group.
- Incidence of neonatal mortality [ Time Frame: First 28 days after birth ]The incidence of neonatal mortality (infants death during the first 28 days after birth) will be reported in each group.
- Incidence of early neonatal mortality [ Time Frame: First 7 days after birth ]The incidence of early neonatal mortality (infants death during the first 7 days after birth) will be reported in each group.
- Incidence of pregnancy complications: hypertension, preeclampsia, antepartum haemorrhage, and infections [ Time Frame: After enrollment until at delivery ]Pregnancy complications (hypertension, preeclampsia, antepartum haemorrhage, and infections) will be diagnosed by trained clinicians during antenatal care checks. All information will be recorded in the pregnant women's medical records of antenatal care checks and delivery. The incidence of hypertension, preeclampsia, antepartum haemorrhage, and infections among participants will be reported in each group.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02537392
|Contact: Hong Yan, Professorfirstname.lastname@example.org|
|Contact: Jiaomei Yang, Graduateemail@example.com|
|Xi'an Jiaotong University College of Medicine||Recruiting|
|Xi'an, Shaanxi, China, 710061|
|Contact: Hong Yan, Professor 13991802320 firstname.lastname@example.org|
|Contact: Jiaomei Yang, Graduate 15829697385 email@example.com|
|Principal Investigator:||Hong Yan, Professor||Health Science Center of Xi’an Jiaotong University|